On Nov. 17, 2020, Moderna announced that the European Medicines Agency (EMA) human medicines committee (CHMP) hah started a rolling review of mRNA-1273, the Companyﾒs vaccine candidate against COVID-19, following the confirmation of eligibility of mRNA-1273 for submission on October 14, 2020.